NCT00721669View on ClinicalTrials.gov

A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

October 31, 2012

Study Completion Date

December 31, 2012

Conditions
Solid Tumor
Interventions
DRUG

IMGN388

IMGN388 is a human IgG1 anti-integrin antibody conjugated to the maytansinoid, DM4.

Trial Locations (3)

33905

Florida Cancer Specialists, Fort Myers

73104

University of Oklahoma, Oklahoma City

Unknown

Sarah Cannon Research Institute, Nashville

Sponsors

Lead Sponsor

ImmunoGen, Inc.
All Listed Sponsors
lead

ImmunoGen, Inc.

INDUSTRY

NCT00721669 - A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors | Biotech Hunter | Biotech Hunter